IMVT

Immunovant (IMVT)

About Immunovant (IMVT)

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Details

Daily high

$30.63

Daily low

$29.67

Price at open

$29.86

52 Week High

$45.58

52 Week Low

$24.67

Market cap

4.4B

Dividend yield

0.00%

Volume

493,775

Avg. volume

845,943

P/E ratio

-15.61

Immunovant News